Alibaba Health Information Technology Limited
0241
Rank in Stocks
#2936
Alibaba Health Information Technology Limited, an investment holding company,... Alibaba Health Information Technology Limited, an investment holding company, engages in the pharmaceutical direct sales, pharmaceutical e-commerce platform, and healthcare and digital services businesses in Mainland China and Hong Kong. The company offers a range of prescription and over-the-counter drugs, nutritional supplements, medical devices, contact lenses, healthcare food, adult and family planning products, and various other health-related products. It also provides medical and healthcare services, including medical checkups, medical consultation, appointment-booking, vaccination, dental and mental care, optometry, and nursing services, as well as traditional chinese medicines. The company provides products and services to business-to-customer and business-to-business customers through offline pharmacy outlets, as well as online stores, such as Tmall, Taobao, Alipay, Ele.me, AMap, DingTalk, Freshippo, and Quark. In addition, it engages in the digital tracking business; asset management; network hospital, software technical services, healthcare related internet information and technical services and research; operation of internet hospitals, as well as Alibaba Health, flagship platform of Alibaba Group for integrated online and offline medical and healthcare resources, providing one-stop healthcare solutions. The company was formerly known as CITIC 21CN Company Limited and changed its name to Alibaba Health Information Technology Limited in September 2014. Alibaba Health Information Technology Limited was incorporated in 1998 and is based in Causeway Bay, Hong Kong.
Share Price
$0.390175
Last synced: 2026-10-20
Market Cap
$6.31B
Change (1 day)
1.50%
Change (1 year)
-50.53%
Country
HK
Trade Alibaba Health Information Technology Limited (0241)
Category
Healthcare
P/E ratio for Alibaba Health Information Technology Limited (0241)
P/E ratio as of October 2026 TTM: 20.75
According to Alibaba Health Information Technology Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 20.75. At the end of 2024 the company had a P/E ratio of 45.22.
P/E ratio history for Alibaba Health Information Technology Limited from 2004 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 20.75 | -57.88% |
| 2025 | 49.27 | 8.94% |
| 2024 | 45.22 | -63.88% |
| 2023 | 125.22 | -160.00% |
| 2022 | -208.70 | -129.63% |
| 2021 | 704.30 | -103.28% |
| 2020 | -21.44K | 2,011.22% |
| 2019 | -1.02K | 279.53% |
| 2018 | -267.62 | 119.20% |
| 2017 | -122.09 | -27.23% |
| 2016 | -167.77 | -67.80% |
| 2015 | -521.04 | -84.11% |
| 2014 | -3.28K | 8,214.77% |
| 2013 | -39.45 | -82.87% |
| 2012 | -230.32 | 46.15% |
| 2011 | -157.59 | 25.02% |
| 2010 | -126.05 | 3,538.25% |
| 2009 | -3.46 | -85.86% |
| 2008 | -24.49 | -46.94% |
| 2007 | -46.17 | -107.88% |
| 2006 | 586.00 | 28.82% |
| 2005 | 454.91 | -128.53% |
| 2004 | -1.59K | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 19.68 | -5.20% |
US
|
|
| 64.40 | 210.31% |
AU
|
|
| 44.30 | 113.46% |
US
|
|
| -47.78 | -330.20% |
US
|
|
| -123.90 | -696.99% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.